ATE295731T1 - Olanzapine zur behandlung von drogenmissbrauch - Google Patents

Olanzapine zur behandlung von drogenmissbrauch

Info

Publication number
ATE295731T1
ATE295731T1 AT97908871T AT97908871T ATE295731T1 AT E295731 T1 ATE295731 T1 AT E295731T1 AT 97908871 T AT97908871 T AT 97908871T AT 97908871 T AT97908871 T AT 97908871T AT E295731 T1 ATE295731 T1 AT E295731T1
Authority
AT
Austria
Prior art keywords
olnzapine
treatment
drug abuse
olanzapine
administering
Prior art date
Application number
AT97908871T
Other languages
English (en)
Inventor
Charles M Beasley Jr
Kurt Rasmussen
Gary D Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606617.0A external-priority patent/GB9606617D0/en
Priority claimed from GBGB9606615.4A external-priority patent/GB9606615D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE295731T1 publication Critical patent/ATE295731T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Disintegrating Or Milling (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Steroid Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
AT97908871T 1996-03-11 1997-03-10 Olanzapine zur behandlung von drogenmissbrauch ATE295731T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1316196P 1996-03-11 1996-03-11
US1316096P 1996-03-11 1996-03-11
GBGB9606617.0A GB9606617D0 (en) 1996-03-29 1996-03-29 Method for treating substance abuse
GBGB9606615.4A GB9606615D0 (en) 1996-03-29 1996-03-29 Method for treating alcohol addiction
PCT/US1997/003404 WO1997033586A1 (en) 1996-03-11 1997-03-10 Method for treating substance abuse

Publications (1)

Publication Number Publication Date
ATE295731T1 true ATE295731T1 (de) 2005-06-15

Family

ID=27451428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97908871T ATE295731T1 (de) 1996-03-11 1997-03-10 Olanzapine zur behandlung von drogenmissbrauch

Country Status (15)

Country Link
EP (1) EP1007050B1 (de)
JP (1) JP2000517287A (de)
KR (1) KR19990087714A (de)
CN (1) CN1213308A (de)
AT (1) ATE295731T1 (de)
BR (1) BR9708037A (de)
CA (1) CA2248738A1 (de)
CZ (1) CZ290398A3 (de)
DE (1) DE69733321D1 (de)
IL (1) IL126158A0 (de)
NO (1) NO984196L (de)
NZ (1) NZ331845A (de)
PL (1) PL328924A1 (de)
TR (1) TR199801801T2 (de)
WO (1) WO1997033586A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU757870B2 (en) * 1998-11-23 2003-03-06 Sepracor, Inc. Pharmaceutical compositions containing olanzapine-N-oxide
EP1133299A1 (de) 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine enthaltende zusammensetzungen und verfahren
DE69923081T2 (de) 1998-11-23 2005-12-08 Sepracor Inc., Marlborough Desmethylolanzapine enthaltende zusammensetzungen und verfahren
WO2002055093A2 (en) * 2001-01-12 2002-07-18 Innovation Ventures, Llc Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605911A (en) * 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal

Also Published As

Publication number Publication date
IL126158A0 (en) 1999-05-09
NZ331845A (en) 2000-09-29
AU2067297A (en) 1997-10-01
CA2248738A1 (en) 1997-09-18
CZ290398A3 (cs) 1999-10-13
TR199801801T2 (xx) 1998-12-21
BR9708037A (pt) 1999-07-27
WO1997033586A1 (en) 1997-09-18
EP1007050A4 (de) 2000-06-14
NO984196D0 (no) 1998-09-11
PL328924A1 (en) 1999-03-01
DE69733321D1 (de) 2005-06-23
CN1213308A (zh) 1999-04-07
EP1007050A1 (de) 2000-06-14
JP2000517287A (ja) 2000-12-26
AU725940B2 (en) 2000-10-26
NO984196L (no) 1998-11-03
EP1007050B1 (de) 2005-05-18
KR19990087714A (ko) 1999-12-27

Similar Documents

Publication Publication Date Title
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
ATE510542T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ATE222109T1 (de) Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
NO984198L (no) FremgangsmÕte for behandling av aggresjon
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
DE69800906D1 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
RU97110384A (ru) Способ лечения вибрационной болезни
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
EA199800818A1 (ru) Способ лечения бессонницы
YU40198A (sh) Postupak za tretiranje zavisnosti od supstance
ATA17797A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
ATA157396A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties